Plain-English translation of NCT03896269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called (CPX-351) in patients whose myelodysplastic syndrome or chronic myelomonocytic leukemia has not responded to or has returned after standard chemotherapy treatments. The medication is given by infusion into a vein. This study aims to find the right dose of the medication and to see how well it works against these blood cancers.
When these types of blood cancers stop responding to the standard first-line drugs, patients have very few treatment options left. This trial is testing whether this medication, which packages two cancer-fighting drugs together in a special coating, can help patients whose cancers have become resistant to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (into a vein) over 90 minutes on specific days. The first phase involves three infusions given on days 1, 3, and 5. Depending on your response and side effects, you may continue with a second phase of treatment lasting up to 24 cycles (about 2 years total), with infusions given every 28 days. You will have regular blood tests and medical visits to monitor how the treatment is working and watch for side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States